EPAM Systems (EPAM) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
15 Apr, 2026Voting matters and shareholder proposals
Seven proposals will be voted on, including director elections, charter amendments, ratification of auditors, executive compensation, amendments to incentive and employee stock purchase plans, and a shareholder proposal for special meeting rights.
Each proposal specifies the required majority for approval and details the effects of abstentions and broker non-votes, with most requiring a majority of shares present or represented by proxy.
Abstentions generally count as votes against, except in director elections where they have no effect; broker non-votes typically have no effect except for the charter amendment.
The shareholder proposal seeks to allow shareholders the ability to call special meetings, requiring a majority of shares present or represented by proxy for approval.
Board of directors and corporate governance
Directors are elected by a majority of votes cast for each nominee, with abstentions and broker non-votes having no effect on the outcome.
Executive compensation and say-on-pay
An annual advisory vote on executive compensation is included, requiring a majority of shares present or represented by proxy; abstentions count as votes against, broker non-votes have no effect.
Amendment to the 2025 Long Term Incentive Plan is proposed due to limited shares available for issuance; failure to approve limits future equity awards.
Latest events from EPAM Systems
- Accelerating as an AI-native leader, targeting 16%+ margins and $1.8B+ free cash flow by 2028.EPAM
Investor Day 202613 Apr 2026 - Annual meeting covers director elections, auditor ratification, and key shareholder rights proposals.EPAM
Proxy filing6 Apr 2026 - Board backs governance, compensation, and equity plan changes; opposes lower special meeting threshold.EPAM
Proxy filing6 Apr 2026 - Shareholders will vote on director elections, equity plan amendments, and expanded governance rights.EPAM
Proxy filing26 Mar 2026 - Strong 2025 growth and AI momentum support a robust 2026 outlook for revenue and EPS.EPAM
Q4 202519 Feb 2026 - Q2 revenue down 2% YoY; healthcare strong, margins lower, new $500M buyback approved.EPAM
Q2 20242 Feb 2026 - Q3 revenue and EPS rose, NEORIS acquisition expanded reach, and share buybacks accelerated.EPAM
Q3 202416 Jan 2026 - Q4 2024 delivered strong growth and 2025 guidance targets double-digit revenue gains.EPAM
Q4 202413 Dec 2025 - Board declassification, majority voting, and new incentive plan headline 2025 proxy.EPAM
Proxy Filing1 Dec 2025